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Background: A study was undertaken to investigate the aerobic capacity and pulmonary function of
children 6 and 15 months after the diagnosis of severe acute respiratory syndrome (SARS).
Methods: Thirty four patients of mean age 14.7 years completed both pulmonary function and maximal
aerobic capacity tests at 6 months. All had normal clinical examination and were asymptomatic. Their
exercise responses were compared with a group of healthy controls. Complete data were collected on 27
of the original 34 cases at 15 months.
Results: Compared with normal controls, the patient group had significantly lower absolute and mass
related peak oxygen consumption (peak V˙O2 (p,0.01)), higher ventilatory equivalent for oxygen
(p,0.01), lower oxygen pulse (p,0.01), and a lower oxygen uptake efficiency slope (p,0.01) at
6 months. This impairment was unexpected and out of proportion with the degree of lung function
abnormality. Residual high resolution computed tomography of thorax (HRCT) abnormalities were present
in 14 patients. Those with abnormal HRCT findings had significantly lower mass related peak V˙O2 than
subjects with normal radiology (p,0.01). Absolute and mass related peak V˙O2 in the patient group
remained impaired at 15 months despite normalisation of lung function in all patients.
Conclusions: The mechanism for the reduced aerobic capacity in children following SARS is not fully
understood, but it is probably a consequence of impaired perfusion to the lungs at peak exercise and
deconditioning.
S
evere acute respiratory syndrome (SARS) is a contagious
respiratory infection caused by the SARS coronavirus
(SARS CoV).1 In adults a mortality rate of around 10% has
been reported, and pulmonary complications in the form of
pulmonary fibrosis and bronchiectasis may be as high as 20% in
survivors.2 A number of adult patients complained of limitations
in physical function from general weakness and/or shortness of
breath after recovery from the disease.3 The disease spectrum
and progression are, however, different in children. No fatalities
were reported in children and the clinical course and
radiological changes were much milder.4–6 Six months after
diagnosis, all 47 children with SARS had complete clinical
recovery and .90% had normal lung function.7
The individual response to exercise is an important clinical
assessment tool since it provides a composite evaluation of
the respiratory, cardiac, and metabolic systems. Exercise
testing is thus a more reliable assessment method of
functional outcome than resting pulmonary function tests.
Aerobic exercise capacity impairment has been reported in
adults and adolescents following HIV infection.8 9 Ong et al10
have recently shown that, 3 months after hospital discharge,
41% of adult SARS survivors had reduced aerobic capacity
that could not be adequately explained solely by impaired
pulmonary function. They suggested that the reduced
exercise capacity was probably related to myopathy or
physical deconditioning. Whether children affected by
SARS have similar a sequel and its progress with time has
not been reported. This study aimed to assess the aerobic
capacity and pulmonary function of children 6 and
15 months after an acute episode of SARS.
METHODS
Subjects
The patient group comprised children who had previously
received hospital treatment for SARS at one of the five
participating paediatric centres in Hong Kong who satisfied
the following inclusion criteria: (1) serological confirmation
of SARS-CoV infection, (2) age less than 18 years at the time
of diagnosis, (3) 6 months had elapsed since the diagnosis of
SARS was made, and (4) no upper respiratory tract infection
symptoms during the 2 weeks before the study. This study
was approved by the ethics review board of the Chinese
University of Hong Kong. Written consent was obtained from
the subjects and their parents.
A control group was drawn from a cohort of 147 healthy
children matched for sex, age and height. These children
were recruited from 10 randomly chosen government funded
schools in Hong Kong to participate in a separate study,11 and
written parental and child consent were obtained.
Abbreviations: FEV1, forced expiratory volume in 1 second; FEF25–75,
mid forced expiratory flow; FRC, functional residual capacity; FVC,
forced vital capacity; HR, heart rate; OUES, oxygen uptake efficiency
slope; PETO2, end tidal oxygen partial pressure; PETCO2, end tidal carbon
dioxide partial pressure; PFT, pulmonary function test; RER, respiratory
exchange ratio; RR, respiratory rate; TLC, total lung capacity; TLCO,
carbon monoxide transfer factor; VAT, ventilatory anaerobic threshold;
V˙E, minute ventilation; V˙O2, oxygen consumption; V˙E/V˙O2, ventilatory
equivalent for oxygen; V˙E/V˙CO2, ventilatory equivalent for carbon
dioxide
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Assessments of children in patient group
Eligible subjects were invited to undergo assessment at 6 and
15 months after the diagnosis of SARS was made. During the
visit the subjects were interviewed and underwent a physical
examination. Their body mass was measured using an
electronic body weight scale (Seca Delta Model 707) and
their height was measured with a Harpenden stadiometer. All
subjects then underwent pulmonary function tests (PFTs),
high resolution computed tomography of the thorax (HRCT),
and a maximal treadmill exercise test. The methodological
details of the PFTs and HRCT have been described elsewhere.7
In brief, PFTs were carried out according to the recommended
standard.12 Forced expiratory volume in 1 second (FEV1) and
forced vital capacity (FVC) were measured using spirometry
(Medical Graphics Pulmonary Function System with
BreezeSuite Software, Medical Graphics Corporation, St
Paul, MN, USA), total lung capacity (TLC) was measured
by body plethysmography (MedGraphics elite Series
Plethysmography) and lung transfer factor (TLCO) by the
single breath carbon monoxide technique. The PFT results
were expressed as percentages of predicted normal values
using local references.13
HRCT scans were assessed using a multidetector scanner
(LightSpeed16; GE Medical Systems, Milwaukee, USA).
During this procedure, subjects were in a supine position
and performed breath holding at full inspiration and at
maximal expiration. All images were reviewed by a paediatric
radiologist for the presence and distribution of residual
radiological abnormalities. The radiologist was blinded to the
clinical information and pulmonary status of the subjects.
Fifteen months after the diagnosis of SARS, all subjects
who had successfully completed the maximal exercise test at
6 months were invited to return for repeat assessments. Only
those with abnormal HRCT scans at 6 months underwent
repeat scanning at 15 months.
Maximal treadmill exercise test
The testing procedure was explained after arrival at the
exercise laboratory. Subjects were then given time to practice
on the treadmill before the formal exercise test. Aerobic
capacity was assessed using an electromechanical treadmill
(GE Marquette Medical Systems with centre ETT system,
Advanced BioSystems, FL, USA) which was programmed
according to the Bruce protocol.14 After a steady resting
period, subjects were asked to walk on the treadmill at a
speed of 1.7 mph and a gradient of 10% for 3 minutes. The
speed and grade were then increased by 0.8 mph and 2%
respectively every 3 minutes until the treadmill reached
5 mph and 18% gradient. After this the speed was increased
by 0.5 mph every 3 minutes. Breath by breath gas samples
were collected using a comfortably fitted facemask (Hans
Rudolph paediatric large size, 8950 series) and analysed
throughout the test by open circuit calorimetry using the
Medgraphics System CPX/D metabolic cart (Medical Graphics
Corporation, St Paul, MN, USA). Care was taken to ensure
complete safety and a physician was present during the
whole procedure. The heart rate was monitored continuously
during the test. A maximum effort during the test was
assumed when two of the following three conditions were
reached: (1) respiratory exchange ratio (RER) .1.0; (2) heart
rate .95% of predicted maximum;15 16 (3) clear signs of
exhaustion (facial flushing, unsteady gait) and refusal to
carry on despite strong verbal encouragement.
Gas exchange data at peak exercise were recorded.
Submaximal responses including the ventilatory anaerobic
threshold (VAT) and the oxygen uptake efficiency slope
(OUES) were also documented. VAT was defined as the level
of oxygen consumption (V˙O2) at which one of the following
diagnostic criteria had been satisfied: (1) an increase in
ventilatory equivalent for oxygen (V˙E/V˙O2) without a simul-
taneous decrease in ventilatory equivalent for carbon dioxide
(V˙E/V˙CO2); (2) an increase in end tidal oxygen partial
pressure (PETO2) without a simultaneous decrease in end
tidal carbon dioxide partial pressure (PETCO2); and (3) the V-
slope method.17 The OUES represented the rate of increase in
V˙O2 in response to minute ventilation (V˙E) and is described
by the following exponential function:
V˙O2 = a 6 log V˙E + b
where a represents the rate of increase in V˙O2 in response to
V˙E and b is a constant.18
The OUES and maximal exercise responses of the control
healthy children were used for comparison.
Statistical analysis
Anthropometric measurements of the subjects and normal
controls were compared using the Student’s t test. A
generalised linear model (GLM) was performed to compare
pulmonary function outcomes and exercise responses
6 months after the diagnosis of SARS between the subjects
and controls adjusted for the z score of weight for age.
Pearson correlation coefficients were used to determine an
association between subjects’ resting lung function and the
endurance parameters, and to assess the association between
the z score of weight for age and the change in exercise
responses between 6 and 15 months from the diagnosis of
SARS. Analysis of covariance (ANCOVA) was used to
compare the change in exercise responses over the two time
periods for the subgroups, which were classified according to
their HRCT results. Paired t tests were used to compare the
exercise responses within the subgroups. The x2 test was
performed to compare the recorded symptoms at the end of
the exercise test. All statistical analyses were carried out
using SPSS for Windows Release 13.0 (SPSS Inc, Chicago, IL,
USA) and the level of significance was set at 5%.
RESULTS
Forty seven patients (45% female) were recruited and
participated in the assessment at 6 months. None of the
patients required readmission following discharge from
hospital. They were all clinically asymptomatic and had
normal clinical examination. Two patients suffered from
allergic rhinitis for which they received antihistamine as
required. Three patients suffered from asthma; two were
receiving low dose inhaled corticosteroids and the other was
using an inhaled bronchodilator as required. The clinical
presentation, course of recovery, and treatment of this cohort
of patients have been reported elsewhere.7 Eight of the
patients were too young to perform the peak V˙O2 running test
and five did not satisfy the criteria for a maximal effort. The
mean (SE) age of the remaining 34 patients was 14.7
(0.4) years. Five of them required oxygen supplementation
and two required mechanical ventilation during the acute
illness. Data from the 34 patients and 34 controls matched for
race, age, sex, and height were compared. The physical
characteristics of the two groups were similar (table 1).
Table 1 Mean (SE) characteristics of study subjects
SARS patients Controls p value*
Sex (M:F) 21:13 21:13 1.000
Age (years) 14.7 (0.4) 14.0 (0.3) 0.193
Height (cm) 160.3 (2.2) 160.0 (2.2) 0.934
Weight (kg) 55.1 (2.2) 51.6 (2.2) 0.263
BMI (kg/m2) 21.3 (0.6) 19.9 (0.7) 0.143
*p values determined by Student’s t test except for sex which was
determined by the x2 test.
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Maximal and submaximal exercise responses of the patient
and control groups are shown in table 2. At 6 months the
patient group had absolute and mass related peak V˙O2 values
32.5% and 34.9% lower than the control group, respectively
(p,0.05). When compared with Armstrong and Welsman’s
age and sex predicted values,19 the control group recorded
values of 91% predicted (predicted peak V˙O2 2360 (480) ml/
min), similar to previous findings for 13–16 year old Hong
Kong Chinese youngsters,11 while the patients only achieved
values of 61% predicted (predicted peak V˙O2 2460 (610) ml/
min). V˙E was 10.5% lower, although this difference was not
statistically significant, while V˙E/V˙O2 was 40.6% higher in the
patients (p,0.05). The patient group also had a significantly
lower (3%) peak heart rate and 30.4% lower peak O2 pulse
(p,0.05) than the controls. There was, however, no
significant difference in absolute and mass related peak V˙O2
between patients who required oxygen supplementation/
mechanical ventilation and those who did not. The submax-
imal exercise response as reflected by the OUES was 40.6%
lower in the patient group than in the controls (p,0.05).
Pulmonary function testing at 6 months showed a restric-
tive deficit in two subjects and an obstructive deficit in one.
All abnormalities were mild (.70% predicted). There was
therefore discordance in impairment between the exercise
capacity and pulmonary function of our subjects. HRCT
scanning showed that residual ground glass opacification
was present in five subjects, air trapping in six, and a
combination of the two in three. There were no significant
differences in physical characteristics, the use of medications
including systemic corticosteroids during hospitalisation,
length of hospital stay, and lung function parameters
between those with normal and those with abnormal HRCT
scans. A significant association was observed between
functional residual capacity (FRC) by plethysmography and
TLCO (r = 0.552, p = 0.001) and peak V˙O2 (r = 0.493,
p = 0.003). The pulmonary function parameters of patients
with normal and abnormal HRCT scans are shown in table 3.
The exercise responses of the subjects by normal and
abnormal HRCT findings are summarised in table 4. Subjects
with abnormal HRCT scans had a 24.6% lower mass related
peak V˙O2 (p = 0.008) and a higher peak V˙E/V˙O2 (p = 0.049)
than those with normal HRCT scans.
Seven of the 34 subjects for whom exercise data were
available at 6 months did not return for reassessment at
15 months. The rest had normal pulmonary function at
15 months. There was no association between the z score of
weight for age and the change in exercise responses between
6 and 15 months. The absolute and mass related peak V˙O2
increased at 15 months but still remained suboptimal
compared with normal controls (table 5). The respiratory
rate, V˙E, V˙E/V˙O2 and V˙E/V˙CO2 of the patients decreased
significantly (p,0.05) while PETO2 and PETCO2- increased. In
addition, oxygen pulse at peak exercise and the OUES
increased significantly at 15 months compared with the
values at 6 months.
Of the initial 14 subjects with abnormal HRCT scans at
6 months, two did not return for rescanning. The HRCT
findings did not show significant interval changes for the
remaining 12 patients. The exercise responses of the subjects
with normal and abnormal HRCT scans are shown in table 6.
ANCOVA did not show significant differences in the change
in exercise responses in the two subgroups over the 9 month
period. Within group comparisons showed that both sub-
groups had significant improvements in V˙E/V˙O2 (difference
(95% CI) between normal and abnormal HRCT results 29.9
(216.2 to 23.7) and 213.6 (219.5 to 27.7), p = 0.004 and
p,0.0005, respectively), V˙E/V˙CO2 (28.8 (214.0 to 23.6) and
211.3 (216.4 to 26.1), p = 0.003 and p = 0.001), PETO2 (12.9
Table 2 Maximal and submaximal exercise responses 6 months after SARS diagnosis
Adjusted mean (SE)*
Adjusted mean difference
(95% CI) p value
Patients
(n = 34)
Controls
(n = 34)
Peak V˙O2 (ml/min) 1479.5 (102.6) 2194.8 (102.6) 2715.3 (21006.4 to 2424.2) ,0.0005
Peak V˙O2 (ml/kg/min) 27.4 (1.3) 42.3 (1.3) 214.8 (218.6 to 211.0) ,0.0005
Peak RER 1.2 (0.01) 1.1 (0.01) 0.09 (0.05 to 0.13) ,0.0005
Peak heart rate (beats/min) 192.9 (1.3) 199.9 (1.3) 26.9 (210.5 to 23.4) ,0.0005
Peak O2 pulse (ml/beat) 7.7 (0.5) 11.2 (0.6) 23.4 (25.0 to 21.9) ,0.0005
Peak respiratory rate (breaths/min) 51.0 (1.8) 52.8 (1.8) 21.8 (26.8 to 3.2) 0.474
Peak V˙E (l/min) 67.9 (2.9) 75.9 (2.9) 28.0 (216.3 to 0.3) 0.059
Peak V˙E/V˙O2 49.1 (1.4) 35.0 (1.4) 14.2 (10.1 to 18.2) ,0.0005
OUES 634.8 (45.5) 1068.4 (47.4) 2433.6 (2565.4 to 2301.8) ,0.0005
V˙O2, oxygen consumption; V˙E, minute ventilation; RER, respiratory exchange ratio; OUES, oxygen uptake efficiency slope.
Values are adjusted for the z score of weight for age.
Table 3 Pulmonary function tests in patients by HRCT findings 6 months after SARS diagnosis
Adjusted mean (SE)*
Adjusted mean difference
(95% CI) p value
Normal HRCT scan
(n = 20)
Abnormal HRCT scan
(n = 14)
FVC (% predicted) 93.6(2.7) 89.6 (3.1) 23.9 (212.3 to 4.5) 0.348
FEV1 (% predicted) 90.0 (2.3) 86.4 (2.7) 23.7 (210.8 to 3.5) 0.309
FEV1/FVC (% predicted) 96.5 (2.1) 97.8 (2.5) 1.3 (25.3 to 7.9) 0.687
FEF25–75 (% predicted) 87.6 (5.3) 86.6 (6.2) 21.0 (217.8 to 15.7) 0.900
TLC (% predicted) 100.5 (3.7) 101.3 (4.2) 0.8 (210.7 to 12.2) 0.893
FRC (pleth) (l) 2.2 (0.1) 2.1 (0.2) 20.1 (20.6 to 0.3) 0.512
TLCO (ml/min/mm Hg) 23.6 (2.0) 21.2 (2.2) 22.4 (28.6 to 3.8) 0.431
TLCO (% predicted) 116.6 (7.5) 107.0 (8.2) 29.6 (232.3 to 13.1) 0.397
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FRC, functional residual capacity; FEF25–75, mid forced expiratory flow; TLC, total lung
capacity; TLCO, carbon monoxide transfer factor.
*Values are adjusted for the z score of weight for age.
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(2.3 to 23.6) and 24.6 (14.0 to 35.2) mm Hg, p = 0.021 and
p,0.0005) and PETCO2 (6.5 (2.5 to 10.5) and 8.8 (5.1 to
12.6) mm Hg, p = 0.004 and p,0.0005) at peak exercise at
15 months. Those with abnormal HRCT scans also showed
significant improvements in absolute peak V˙O2 (difference
(95% CI) 296.8 (112.8 to 480.9) ml/min, p = 0.005) and mass
related peak V˙O2 (4.6 (1.2 to 7.9) ml/kg/min, p = 0.012), peak
oxygen pulse (1.7 (0.7 to 2.6) ml/beat, p = 0.002), peak
respiratory rate (25.9 (211.2 to 20.7) breaths/min,
p = 0.031), VAT (181.3 (67.1 to 295.6) ml/min, p = 0.005),
and OUES (112.3 (13.2 to 211.4), p = 0.030) at 15 months
compared with values at 6 months.
At 6 months after diagnosis 85% of the patients with
normal HRCT scans reported leg fatigue and 10% reported
breathlessness as the reason for terminating the exercise test.
For those with abnormal HRCT scans, 84.6% reported leg
fatigue and 7% reported breathlessness as their reason for
test termination (p = 0.525). At 15 months after diagnosis
91% of the patients with normal HRCT scans reported leg
fatigue but none gave breathlessness as their reason for
terminating the exercise test; the corresponding figures for
the those with abnormal HRCT scans were 90% and 10%,
respectively (p = 0.366).
DISCUSSION
Studies examining the sequelae of SARS are limited and most
have concentrated on the early phases of rehabilitation (1–
6 months).3 7 10 20 21 To the best of our knowledge, this is the
first study to examine later stage recovery in children and
adolescents who contracted the SARS CoV. The main
Table 4 Maximal and submaximal exercise responses in patients by HRCT findings 6 months after SARS diagnosis
Adjusted mean (SE)*
Adjusted mean difference
(95% CI) p value
Normal HRCT scan
(n = 20)
Abnormal HRCT scan
(n = 14)
Resting V˙O2 (ml/min) 229.3 (13.3) 201.6 (15.9) 227.8 (270.3 to 14.8) 0.193
Respiratory quotient 0.87 (0.02) 0.86 (0.02) 20.01 (20.06 to 0.04) 0.752
Resting HR (beats/min) 88.3 (3.3) 86.7 (3.9) 21.6 (212.1 to 8.9) 0.753
Resting RR (breaths/min) 18.8 (1.0) 19.7 (1.2) 0.9 (22.4 to 4.2) 0.572
Resting V˙E (l/min) 9.1 (0.4) 8.8 (0.5) 20.3 (21.6 to 1.0) 0.620
Peak V˙O2 (ml/min) 1668.9 (131.9) 1294.0 (158.1) 2374.9 (2797.8 to 48.1) 0.080
Peak V˙O2 (ml/kg/min) 30.5 (1.7) 23.0 (2.0) 27.5 (212.9 to 22.1) 0.008
Peak RER 1.2 (0.02) 1.2 (0.02) 0.04 (20.02 to 0.10) 0.153
Peak HR (beats/min) 193.4 (2.0) 192.7 (2.4) 20.7 (27.1 to 5.7) 0.823
Peak O2 pulse (ml/beat) 8.7 (0.7) 6.7 (0.9) 22.1 (24.4 to 0.3) 0.080
Peak RR (breaths/min) 50.5 (2.4) 51.6 (2.9) 1.1 (26.6 to 8.8) 0.689
Peak V˙E (l/min) 71.8 (3.6) 65.2 (4.3) 26.6 (218.0 to 4.9) 0.250
Peak V˙E/V˙O2 45.8 (2.4) 53.5 (2.8) 7.7 (0.1 to 15.3) 0.049
Peak V˙E/V˙CO2 40.0 (2.0) 44.4 (2.4) 4.4 (22.0 to 10.7) 0.172
PETO2 (mm Hg) 93.0 (3.6) 91.0 (4.3) 22.1 (213.5 to 9.3) 0.714
PETCO2 (mm Hg) 32.5 (1.7) 29.4 (2.0) 23.0 (28.3 to 2.2) 0.248
VAT (ml/min) 979.4 (78.7) 793.3 (94.4) 2186.1 (2438.5 to 66.3) 0.143
OUES 712.7 (62.6) 562.9 (71.9) 2149.8 (2344.9 to 45.3) 0.128
Exercise time (s) 602.2 (48.0) 569.2 (61.9) 233.0 (2194.0 to 127.9) 0.679
V˙O2, oxygen consumption; V˙E, minute ventilation; HR, heart rate; RER, respiratory exchange ratio; RR, respiratory rate; V˙E/V˙O2, V˙E/V˙CO2, ventilatory equivalent
for oxygen and carbon dioxide; PETO2, PETCO2, end tidal oxygen and carbon dioxide partial pressures; VAT, ventilatory anaerobic threshold; OUES, oxygen
uptake efficiency slope.
*Values are adjusted for the z score of weight for age.
Table 5 Mean (SE) physical characteristics and exercise responses of 27 patients 6 and 15 months after SARS diagnosis
6 months 15 months Difference (95% CI) p value*
Height (cm) 160.6 (2.5) 162.3 (2.4) 1.7 (1.0 to 2.4) ,0.0005
Weight (kg) 56.7 (2.6) 58.3 (2.6) 1.6 (0.4 to 2.8) 0.008
BMI (kg/m2) 21.8 (0.7) 22.0 (0.8) 0.2 (20.2 to 0.6) 0.313
Resting V˙O2 (ml/min) 228.3 (11.3) 233.6 (14.9) 5.3 (222.8 to 33.4) 0.702
Respiratory quotient 0.86 (0.01) 0.83 (0.02) 20.03 (20.06 to 0.00) 0.062
Resting HR (beats/min) 87.3 (2.4) 81.5 (2.7) 25.8 (211.0 to 20.6) 0.032
Resting RR (breaths/min) 19.7 (0.9) 19.1 (0.9) 20.63 (22.1 to 0.8) 0.376
Resting V˙E (l/min) 9.1 (0.3) 8.3 (0.4) 20.9 (21.76 to 0.02) 0.058
Peak V˙O2 (ml/min) 1595.6 (127.5) 1780.4 (95.6) 112.8 (260.4 to 286.0) 0.192
Peak V˙O2 (ml/kg/min) 28.0 (1.7) 29.6 (1.2) 1.6 (21.6 to 4.8) 0.306
Peak RER 1.2 (0.0) 1.2 (0.0) 0.00 (20.04 to 0.05) 0.861
Peak HR (beats/min) 192.8 (1.7) 190.8 (1.6) 22.0 (24.9 to 0.8) 0.153
Peak O2 pulse (ml/beat) 8.3 (0.7) 8.9 (0.5) 0.6 (20.4 to 1.6) 0.217
Peak RR (breaths/min) 51.0 (2.2) 46.6 (2.0) 24.4 (28.1 to 20.7) 0.022
Peak V˙E (l/min) 70.5 (3.4) 61.3 (3.7) 29.1 (216.5 to 21.8) 0.017
Peak V˙E/V˙O2 (mm Hg) 47.8 (2.3) 36.2 (1.0) 211.6 (215.7 to 27.4) ,0.0005
Peak V˙E/V˙CO2 (mm Hg) 39.8 (2.0) 30.0 (0.8) 29.9 (213.3 to 26.4) ,0.0005
PETO2 (mm Hg) 95.2 (3.1) 113.3 (0.9) 18.1 (10.7 to 25.5) ,0.0005
PETCO2 (mm Hg) 32.7 (1.7) 40.2 (1.0) 7.5 (4.9 to 10.1) ,0.0005
VAT (ml/min) 964.5 (77.9) 1028.4 (54.4) 63.9 (262.5 to 190.2) 0.308
OUES 711.1 (66.8) 822.5 (42.1) 111.4 (16.6 to 206.1) 0.023
Exercise time (s) 626.7 (24.1) 557.9 (17.6) 268.8 (2111.8 to 225.7) 0.003
V˙O2, oxygen consumption; V˙E, minute ventilation; HR, heart rate; RER, respiratory exchange ratio; RR, respiratory rate; O2 pulse, oxygen consumption per heart
beat; V˙E/V˙O2, V˙E/V˙CO2, ventilatory equivalent for oxygen and carbon dioxide; PETO2, PETCO2, end tidal oxygen and carbon dioxide partial pressures; VAT,
ventilatory anaerobic threshold; OUES, oxygen uptake efficiency slope.
*Paired t test.
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findings of the current study were: (1) impairment of aerobic
capacity in asymptomatic children at 6 months which
persisted to 15 months after the diagnosis was made; (2)
those with residual radiological abnormalities had a sig-
nificantly greater reduction in aerobic capacity than those
with normal HRCT scans at 6 months but this association no
longer existed at 15 months; and (3) the reduction in aerobic
capacity appears to be related to impaired lung function but is
probably also the result of deconditioning following this
acute illness.
Studies investigating aerobic capacity following viral
infections are sparse and the few reported studies have
focused on patients with HIV. Decreased aerobic capacity has
been reported in adults and late adolescents infected with
HIV.8 9 22 These studies have shown that peak V˙O2 values were
24–35% below the expected normal target. Several potential
mechanisms—including pulmonary dysfunction, anaemia,
cardiovascular dysfunction, peripheral muscle oxygen extrac-
tion limitation, and deconditioning—have been proposed for
the decreased aerobic capacity in these patients.23 In relation
to SARS CoV infection, a study that examined laboratory
determined aerobic capacity in adult SARS survivors found
that 41% had aerobic capacity values below the lower limit of
a reference norm.10 This reduction in aerobic capacity,
however, could not be accounted for by pulmonary function
impairment alone as the lung function abnormalities were
mild. The self-paced 6 minute walk test (6MWT) was
performed to evaluate the global and integrated responses
to exercise in another cohort of adult SARS survivors.21 The
subjects’ performance on the 6MWT was significantly
impaired, out of proportion to the degree of lung function
abnormality at 6 months following the diagnosis.21
Aerobic capacity impairment was found in our cohort of
asymptomatic patients at 6 months and persisted to
15 months following the diagnosis of SARS. Similar to the
reported literature in adult patients, this reduction in aerobic
capacity occurred despite relatively mild pulmonary function
abnormalities. At 6 months only three of the 34 patients had
abnormal lung function, two with a restrictive deficit and one
with an obstructive deficit; these had returned to normal
when the test was repeated at 15 months. However, the
increased oxygen cost of breathing at maximal exercise noted
indicates altered respiratory muscle dynamics. At 6 months
the patient group had significantly higher V˙E/V˙O2 than
normal controls and, within the patient group, those with
residual radiological abnormalities had an increased V˙E/V˙O2.
An increase in physiological dead space could explain the
abnormal V˙E/V˙O2 seen in our patients as their resting and
peak respiratory rates were found to be comparable to those
of normal controls.17 It is possible that such subtle defective
respiratory muscle dynamics may not have been apparent in
the static lung function test but became apparent when the
patients were subjected to stress.
In the 14 patients with residual radiological abnormalities,
the HRCT scan showed ground glass opacification and/or air
trapping. The presence of ground glass opacification indicates
an increase in the density of soft tissue within the lung, while
not completely filling the air spaces.24 This abnormality would
interfere with normal lung gas exchange, causing reduced
lung compliance and thus further increasing the work of
breathing.25 Air trapping causes a decrease in pulmonary
blood flow and leads to gradual atrophy of the involved
portion of the lung tissue.26 The ventilation of poorly perfused
air spaces increases the physiological dead space, thus
increasing the ventilatory requirement.25 This could explain
why patients with residual radiological abnormalities have a
higher oxygen cost of breathing at maximal exercise than
those with normal radiology.
However, while our data would indicate that the abnormal
respiratory muscle dynamics were related to reduced exercise
capacity, the absolute peak V˙O2 remained suboptimal at
15 months despite the fact that the V˙E/V˙O2 had returned to
normal.
Oxygen pulse was significantly reduced in the patient
group and remained so at 15 months. The oxygen pulse
provides a reflection of oxygen taken up by the pulmonary
blood during the period of a heart beat, the combined product
of stroke volume and the difference between the arterial and
mixed venous blood oxygen content.17 Assuming stroke
volume in our patients remained unaffected on recovery
from SARS (as is seen in adult SARS survivors who had a
more severe disease course),27 it is reasonable to hypothesise
Table 6 Physical characteristics and exercise responses by HRCT findings 15 months after SARS diagnosis
Adjusted mean (SE)*
*Adjusted mean difference
(95% CI) p value
Normal HRCT scan
(n = 15)
Abnormal HRCT scan
(n = 12)
Resting V˙O2 (ml/min) 224.4 (17.9) 243.6 (18.6) 19.2 (235.5 to 73.8) 0.476
Respiratory quotient 0.83 (0.02) 0.84 (0.02) 0.01 (20.05 to 0.07) 0.671
Resting HR (beats/min) 82.8 (3.0) 80.1 (3.1) 22.7 (211.7 to 6.3) 0.542
Resting RR (breaths/min) 19.7 (0.9) 18.4 (0.9) 21.3 (24.1 to 1.4) 0.325
Resting V˙E (l/min) 8.3 (0.5) 8.2 (0.6) 20.1 (21.8 to 1.5) 0.863
Peak V˙O2 (ml/min) 1665.8 (88.7) 1754.2 (92.3) 88.5 (2186.3 to 363.2) 0.512
Peak V˙O2 (ml/kg/min) 30.1 (1.6) 29.0 (1.7) 21.1 (26.3 to 4.1) 0.664
Peak RER 1.2 (0.03) 1.2 (0.03) 0.03 (20.06 to 0.12) 0.473
Peak HR (beats/min) 192.0 (1.8) 189.5 (1.8) 22.5 (27.9 to 2.8) 0.334
Peak O2 pulse (ml/beat) 8.7 (0.4) 9.2 (0.4) 0.5 (20.8 to 1.8) 0.469
Peak RR (breaths/min) 48.4 (2.3) 44.6 (2.3) 23.8 (210.6 to 3.0) 0.256
Peak V˙E (l/min) 61.0 (4.8) 61.7 (5.0) 0.6 (213.9 to 15.1) 0.928
Peak V˙E/V˙O2 36.1 (1.3) 36.3 (1.3) 0.2 (23.8 to 4.3) 0.902
Peak V˙E/V˙CO2 31.1 (0.9) 29.5 (1.0) 21.6 (24.3 to 1.1) 0.236
PETO2 (mm Hg) 113.3 (0.9) 113.3 (1.0) 0.02 (22.9 to 2.9) 0.991
PETCO2 (mm Hg) 39.5 (1.0) 40.7 (1.1) 1.2 (21.9 to 4.3) 0.431
VAT (ml/min) 1033.1 (56.0) 1023.7 (56.0) 29.4 (2181.1 to 162.3) 0.911
OUES 775.6 (40.4) 820.9 (43.5) 45.3 (279.1 to 169.7) 0.460
Exercise time (s) 589.2 (20.8) 524.1 (21.6) 265.1 (2128.9 to 21.2) 0.046
*Values are adjusted for the z score of weight for age and at 6 months.
V˙O2, oxygen consumption; V˙E, minute ventilation; HR, heart rate; RER, respiratory exchange ratio; RR, respiratory rate; O2 pulse, oxygen consumption per heart
beat; V˙E/V˙O2, V˙E/V˙CO2, ventilatory equivalent for oxygen and carbon dioxide; PETO2, PETCO2, end tidal oxygen and carbon dioxide partial pressures; VAT,
ventilatory anaerobic threshold; OUES, oxygen uptake efficiency slope.
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that the decrease in the peak oxygen pulse can be attributed
to the decrease in arteriovenous oxygen difference. This could
be explained by the inefficient ventilation at peak exercise as
a result of increases in physiological dead space which, in
turn, causes a reduction in arterial oxygen tension (PaO2)
during progressively increasing exercise work rate.17 The
arteriovenous oxygen difference is dependent on the avail-
ability of haemoglobin, blood oxygenation in the lung, and
the extraction of oxygen at the periphery. As the patients’
haemoglobin levels were within the normal range,28 blood
oxygenation in the lung and extraction of oxygen at the
periphery are two factors that might have contributed to the
decrease in arteriovenous oxygen difference at peak exercise.
With regard to blood oxygenation in the lung at peak
exercise, increased dead space ventilation was suspected in
our group of patients. Since only perfused alveoli can obtain
carbon dioxide, underperfused alveoli relative to ventilation
would have a low carbon dioxide concentration.17 The
measurement of PETCO2) has been suggested as a reliable
non-invasive estimate of PaCO2.
29 PETCO2 is the partial
pressure of carbon dioxide observed at the end of each
exhalation and ideally reflects the alveolar partial pressure of
this gas. In our study there was a trend towards decreased
PETCO2 in patients with residual radiological abnormalities at
6 months compared with those with normal radiology.
Without hyperventilation, as shown by comparable respira-
tory rates at rest and at peak exercise, a low PETCO2 would
reflect a high degree of alveolar ventilation-perfusion ratio
mismatching.17 PETCO2 was significantly higher in all patients
at 15 months than at 6 months, indicating an improvement
in blood oxygenation in the lungs with time.
Muscle weakness/physical deconditioning could affect
peripheral oxygen extraction. Given the fact that the patient
group achieved a peak heart rate within the age predicted
targets at 6 months, it is unlikely that muscle weakness was
a limiting factor for these patients to achieve a maximal
exercise effort.30 Prolonged confinement and inactivity during
and even after the acute stage of illness could lead to
clinically significant impaired muscle function. SARS-CoV
induced myositis, indicated by raised serum creatine kinase,
might also contribute.4–6 31 Steroid induced myopathy has
been proposed as a cause of muscular impairment in adult
SARS survivors.10 21 This was less likely to be a major
determinant in our group of children as none had received
a prolonged course of corticosteroid treatment. Besides
patients given higher doses of corticosteroids, those who
required oxygen supplementation/mechanical ventilation did
not have a greater reduction in aerobic capacity than those
with milder disease. There is evidence that the impairment in
peak V˙O2 was reversing in some by 15 months since only 19%
of the patients had peak V˙O2 values below 25 ml/kg/min at
15 months compared with 53% at 6 months. However, for
many, improvement in aerobic capacity to normal levels had
not occurred even 15 months after the event.
Physical activity levels of healthy Hong Kong children have
been shown to be low,32 33 and certainly not of the magnitude
necessary to induce improvements in aerobic capacity. Even if
these children had resumed their pre-SARS pattern of
behaviour, it is likely that this activity pattern is congruent
with those of other Hong Kong youngsters and would be
insufficient to make any substantial impact on aerobic capacity.
There is a growing body of information from animal models to
suggest that a range of regulatory factors are altered during
periods of confinement and inactivity and reversal probably
requires a more rigorous programme of structured exercise.34
The measurement of maximal oxygen consumption
(V˙O2max) has been widely used as a standard for cardio-
pulmonary functional reserve. Rather than relying on
maximal responses to exercise, valuable information may
also be collected from submaximal phases.35 We have
evaluated the VAT and OUES for patients as well as healthy
control children. VAT is the most frequently used submax-
imal measurement index and is a gas exchange measurement
that can detect the oxygen uptake non-invasively at the onset
of lactate acidosis.36 37 At 6 months there was a trend for VAT
to be decreased in patients with abnormal HRCT scans
compared with those with normal radiological findings. VAT
in patients with abnormal HRCT scans was increased
significantly at 15 months compared with the value at
6 months, indicating that the distribution of blood to the
working muscle was improving. OUES is a relatively new
submaximal index and is calculated from the slope of the
logarithmic regression curve expressing the relationship
between oxygen uptake and minute ventilation during incre-
mental exercise. The OUES indicates how effectively oxygen is
extracted by the lungs and used in the periphery.18 The greatest
advantage of the OUES is that it is not affected by exercise
intensity and appears to be independent of the treadmill
protocol.18 38 In the current study the patient group had a
significantly lower OUES than the normal controls at
6 months. The development of metabolic acidosis and
increases in physiologic dead space are two factors that can
result in the lowering of the OUES.18 38 During metabolic
acidosis, higher mixed venous lactate levels for the same
amount of work induce excessive carbon dioxide production
which can stimulate ventilation and lead to a lower OUES
value. This was an unlikely occurrence in our patients since
hyperventilation was not observed during the exercise phases.
The lower OUES value in our patients at 6 months was
therefore probably influenced by the physiological dead space.
Patients with abnormal HRCT scans had a significant increase
in OUES at 15 months compared with 6 months, again
suggesting improved perfusion to the lungs with time. The
submaximal findings are consistent with the conclusions
drawn from the maximal responses. Both indicate that the
impairment in aerobic capacity in our group of patients is
probably related to an increased physiological dead space
which results from lung perfusion impairment during exercise.
There are a number of limitations to our study. Firstly,
because of the young age of some patients and the inability of
others to achieve a maximum effort, only data from 34 of the
possible 47 patients were examined. Further analysis showed
that the subjects who were not able to perform the exercise
test had a clinically milder disease course. It is therefore
unlikely that we missed significant lung pathology and
radiological abnormalities from those who did not undergo
the running exercise test. Secondly, no comprehensive direct
assessment of cardiac function was made. It was, however,
unlikely that significant cardiac impairment was present as
the patients had a normal clinical examination and were able
to achieve age predicted maximum heart rates at peak
exercise. Finally, because of issues of ethical acceptability
related to radiation exposure, we did not subject patients
with normal HRCT scans at 6 months to a repeat scan at
15 months. However, we feel that the chance of radiological
abnormalities appearing only at 15 months was unlikely.
This study is the most comprehensive report to date of
exercise responses following SARS in children and adoles-
cents. Aerobic capacity was impaired at 6 and 15 months
after the acute episode of SARS. The mechanism for the
reduced aerobic capacity is not fully understood, but it is
probably a result of impaired perfusion to the lungs at peak
exercise and deconditioning. The time course and/or stimuli
necessary to reverse functional impairments following SARS
in children are not fully understood. Only thorough
continued follow up together with exercise manipulation
will we begin to understand whether later improvements are
possible for all members of this patient group.
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